Steve Morgan
 | Associate Director, Faculty
Phone: 604-822-7012 |
Education
PhD, Economics, University of British Columbia
MA, Economics, Queen’s University
BA (Honours), Economics, University of Western Ontario
Research Interests
- Design and impact of pharmaceutical insurance programs
- Equity in access to necessary medicines
- Causes and consequences of drug expenditure growth
- Appraisal and funding of new health care technologies
- Identifying policies that achieve balance between three often-competing goals: providing equitable access to necessary care, managing health expenditures, and promoting valued innovation
Current Research Projects
- Equity in PharmaCare: measuring access to and financing of prescription drugs within and across population subgroups
- Return on investment from pharmaceutical care: measuring population-based causes and consequences of prescription drug utilization and expenditure
- Best practices in pharmaceutical policy: lessons from abroad
- Incentives for valued health innovation: can we have our cake and eat it too?
Currently Recruiting Graduate Students Interested in the Following Areas
- Political and economic aspects of health and pharmaceutical policies
- Equity in access to health services and medicines
- Ethnic variation in use of medicines
- Processes for making health care funding decisions
- Pricing and reimbursement of patented and non-patented medicines
- Measuring drug safety, effectiveness and value-for-money in the ‘real world’
- Research syntheses (systematic reviews) on key pharmaceutical policy questions
Affiliations and Awards
- Adjunct Associate Professor, School of Health Policy and Management, Faculty of Health, York University
- Associate member, Manitoba Centre for Health Policy, University of Manitoba
- Member, Board of Directors, Canadian Association for Health Services and Policy Research
- Labelle Lectureship in Health Services Research (2007)
- New Investigator award, Canadian Institutes of Health Research (2004)
- Career Investigator award, Michael Smith Foundation for Health Research (2004)
- Inaugural Canadian Associate of the Commonwealth Fund's Harkness Fellowship in Health Care Policy (2001)
Current Graduate Students
- Bryn Lander, PhD Student, Interdisciplinary Studies Understanding the role of the medico-scientific community in translational biomedical research
Courses Currently Taught
- HCEC 510/SPHA 510: Canadian Health Policy and the Healthcare System
- HCEP 542/SPPH 542: Issues in Canadian Health Policy
Publications
Toward an understanding of high performance pharmaceutical policy systems: a ‘triple-A’ framework and example analysis Morgan S, Kennedy J, Boothe K, McMahon M, Roughead E, Watson D. The Open Health Services and Policy Journal (TOHSPJ) 2: 1-9. doi: 10.2174/1874924000902010001Cost-Related Prescription Nonadherence in the United States and Canada Morgan S, Kennedy J. Clinical Therapeutics 31(1): 213-219 doi:10.1016/j.clinthera.2009.01.006
Chronic Catastrophes: Exploring the Concentration & Sustained Nature of Ambulatory Rx Drug Expenditures in the Population of BC Hanley GE, Morgan SG. Social Science and Medicine. 2009, doi:10.1016/j.socscimed.2008.12.008 (Epub 2009 January 8).
The Canadian Rx Atlas, 2nd Edition Morgan SG, Raymond C, Mooney D, Martin D. Vancouver (BC): UBC Centre for Health Services and Policy Research; December 2008.
Pharmaceutical Innovation: Can Health and Economic Goals be Met? Morgan S, Mochrie C. Vancouver (BC): UBC Centre for Health Services and Policy Research; July 2008. [Working Paper]
Breadth, Depth and Agreement Among Provincial Drug Formularies in Canada Morgan SG, Hanley G, Raymond C, Blais R. Forthcoming. Please check back for availability. A link will be provided once available.
The Determinants of Prescription Drug Expenditure … and What to Do About Them Morgan SG. Vancouver (BC): Centre for Health Services and Policy Research; April 2008. [Working Paper]
On the Validity of Area-Based Income Measures to Proxy Household Income Hanley GE and Morgan S. BMC Health Services Research. 2008;8:79.
Balancing Health and Industrial Policy Objectives in the Pharmaceutical Sector: Lessons From Australia Morgan S, McMahon M, Greyson D. Health Policy. 2008 August;87(2):133-145.
Toward a Definition of Pharmaceutical Innovation Morgan SG, Lopert R, Greyson G. Open Medicine. 2008;2(1):E4-7.
The Effect of Evidence-Based Drug Coverage Policies on Pharmaceutical R&D: A Case Study from British Columbia - Full Version Morgan SG, Cunningham C. Healthcare Policy. 2007;3(3):online exclusive.
The Effect of Evidence-Based Drug Coverage Policies on Pharmaceutical R&D: A Case Study from British Columbia - Abridged Version Morgan SG, Cunningham C. Healthcare Policy. 2007;3(3):online exclusive.
Distributional Consequences of the Transition from Age-Based to Income-Based Prescription Drug Coverage in BC, Canada. Hanley GE, Morgan S, Hurley J, Van Doorslaer E. Health Economics. 2008, 17:1379-1392. doi: 10.1002/hec.1337. Epub 2008 Jan 11.
Publicly Funded Medical Savings Accounts: Expenditure and Distributional Impacts in Ontario, Canada. Hurley J, Guindon GE, Rynard V, Morgan S. Health Economics. 2008 October;17(10):1129-1151, doi:10.1002/hec.1310 (Epub 2007 Nov 14).
Pharmaceutical Use and Outcomes: Always a Need for a Sober Second Look. Morgan S, MacGibbon B. Healthcare Policy. 3(1) 2007: 10-24.
Influencing Drug Prices through Formulary-Based Policies: Lessons from New Zealand. Morgan S, Hanley G, McMahon M, Barer M. Healthcare Policy. 3(1) 2007: 1-20.
Direct-to-Consumer Advertising and Expenditures on Prescription Drugs: A Comparison of Experiences in the US and Canada. Morgan SG. Open Medicine 2007;1(1):E37-45.
Antidepressant Utilization in British Columbia from 1996 to 2004: Increasing Prevalence but not Incidence. Raymond CB, Morgan SG, Caetano PA. Psychiatric Services. 2007 January;58(1):79-84.
Income-Based Drug Coverage in British Columbia: Towards an Understanding of the Policy. Morgan S, Coombes M. Healthcare Policy. 2006 November;2(2):92-108.
Incentives for Valued Innovation in the Pharmaceutical Sector: Issues for Consideration by Domestic and International Policy Mak Morgan SG, Greyson D, Hanley G, Kinney E. Report prepared for Health Canada. Vancouver (BC): Centre for Health Services and Policy Research; November 2006.
Health Care Access in Three Nations: Canada, Insured America, and Uninsured America. Kennedy J, Morgan SG. International Journal of Health Services. 2006;36(4):697–717.
Toward a Standard Definition and Measurement of Persistence with Drug Therapy Caetano PA, Lam JMC, Morgan SG . Clinical Therapeutics 28(9): 1411-1424. doi: j.clinthera.2006.09.021
Income-Based Drug Coverage in British Columbia: The Impact on Private and Public Expenditures. Morgan S, Yan L. Healthcare Policy [online exclusive]. 2006 November;2(2):109-110.
Income-Based Drug Coverage in British Columbia: Lessons for BC and the Rest of Canada. Morgan S, Evans RG, Hanley GE, Caetano PA, Black C. Healthcare Policy. 2006 November;2(2):115-127.
Income-Based Drug Coverage in British Columbia: The Impact on Access to Medicines. Caetano PA, Raymond CB, Morgan S, Yan L. Healthcare Policy [online exclusive]. 2006 November;2(2):111-112.
Centralising Drug Review to Improve Coverage Decisions: Economic Lessons From (and For) Canada. Morgan SG, McMahon M, Mitton C. Applied Health Economics and Health Policy. 2006;5(2):67-73.
Income-Based Drug Coverage in British Columbia: The Impact on the Distribution of Financial Burden. Hanley GE, Morgan S, Yan L. Healthcare Policy [online exclusive]. 2006 November;2(2):112-114.
The Canadian Rx Atlas: A Snapshot of Utilization and Expenditure. Morgan, SG. Provincial Reimbursement Advisor. 2006 May: 33-39.
Toward a National Pharmaceuticals Strategy. Morgan SG, Balma C, Wilcox, M-E (editors). A summary of the 2006 health policy conference of the UBC Centre for Health Services and Policy Research; 2006 February 9-10; Vancouver, BC. Vancouver (BC): Centre for Health Services and Policy Research; May 2006.
Centralized Drug Review Processes: Are They Fair? Mitton CR, McMahon M, Morgan S, Gibson J. Social Science and Medicine. 2006 July; 63(1):200-211.
Prescription Drug Expenditures and Population Demographics. Morgan SG. Health Services Research. 2006 April;41(2):411-428.
Centralized Drug Review Processes in Australia, Canada, New Zealand, and the United Kingdom. Morgan SG, McMahon M, Mitton C, Roughead E, Kirk R, Kanavos P, Menon D. Health Affairs. 2006 March/April;25(2):337-347.
Canadian Rx Atlas, 1st edition Morgan S, McMahon M, Lam J, Mooney D, Raymond C. Vancouver (BC): Centre for Health Services and Policy Research; December 2005. (80 pages)
British Columbia Rx Atlas. Morgan S, Schaub P, Mooney D, Lam J, Caetano P, McMahon M, Rahim-Jamal S. Vancouver (BC): Centre for Health Services and Policy Research; December 2005. (67 pages)
Medicine by Media: Did a Critical Television Documentary Affect the Prescribing of Cyproterone Estradiol (Diane-35)? Mintzes B, Morgan S, Bassett KL. Canadian Medical Association Journal. 2005 November 22;173(11):1313-1315.
The Common Drug Review: A NICE start for Canada? McMahon M, Morgan S, Mitton C. Health Policy. 2006 August;77(3):339-351.
Booming Prescription Drug Expenditure: A Population-Based Analysis of Age Dynamics. Morgan SG. Medical Care. 2005 October;43(10):996-1008.
Breakthrough Drugs and Growth in Expenditure on Prescription Drugs in Canada. Morgan S, Bassett KL, Wright JM, Evans R, Barer ML, Caetano P, Black C. British Medical Journal. 2005 October 8;331:815-816, doi:10.1136/bmj.38582.703866.AE (Epub 2005 September 2).
Drug Expenditure Trends in the Canadian Provinces: Magnitude and Causes from 1998 to 2004. Morgan SG. Healthcare Policy. 2005 September;1(1):85-99.
Unleash Desired Innovation, Pay for Relative Value. Morgan S. Unleashing Innovation in Health Systems: Alberta's Symposium on Health; 2005 May 3-5; Calgary, AB [Presentation].
Canadian Prescription Drug Costs Surpass $18 billion. Morgan S. Canadian Medical Association Journal [Commentary]. 2005 May 10;172(10):1323-1324.
First-Line First? Trends in Thiazide Prescribing for Hypertensive Seniors. Morgan S, Bassett KL, Wright JM, Yan L. PLoS Medicine. 2005;2(4):e80.
Persistence with Hypertension Treatment Among Community-Dwelling BC Seniors. Morgan SG, Yan L. Canadian Journal of Clinical Pharmacology. Fall 2004;11(2):e267-e273.
Best Practices: An Outcomes-Based Approach to Decisions About Drug Coverage in British Columbia. Morgan S, Bassett K, Mintzes B. Psychiatric Services: Journal of the American Psychiatric Association. 2004 November;55(11):1230-1232.
Who's the Fairest of Them All? Which Provincial Pharmacare Model Would Best Protect Canadians Against Catastrophic Drug Costs? Coombes ME, Morgan SG, Barer ML, Pagliccia N. Longwoods Review. 2004;2(3):13-26.
Pharmacare Placebo. Morgan S. The View from the West [Commentary]. Winnipeg Free Press. 2004 September 2.
Drug Spending in Canada: Recent Trends and Causes. Morgan S. Medical Care. 2004;42(7):635-642.
Seniors' Prescription Drug Cost Inflation and Cost Containment: Evidence from British Columbia. Morgan SG, Agnew J, Barer ML. Health Policy. 2004 June;68(3):299-307.
Outcomes-Based Drug Coverage in British Columbia. Morgan S, Bassett K, Mintzes B. Health Affairs. 2004;23(3):269-276.
Canadians Confront Health Care Reform. Abelson J, Mendelsohn M, Lavis JN, Morgan SG, Forest P-G, Swinton M. Health Affairs. 2004;23(3):186-193.
Post-Romanow Pharmacare: Last-Dollar First ... First Dollar Lost? Morgan SG, Willison DJ. HealthcarePapers. 2004;4(3):10-20.
Internet Pharmacy: Prices on the Up-and-Up. Morgan S, Hurley J. Canadian Medical Association Journal [Synopsis]. 2004 March 16;170(6):945-946.
US Medicare Reform: Why Drug Companies and Private Insurers are Smiling. Hurley J, Morgan SG. Canadian Medical Association Journal. 2004 February 17;170(4):461-462.
Sources of Variation in Provincial Drug Spending. Morgan SG. Canadian Medical Association Journal. 2004 February 3;170(3):329-330.
The Economics of Direct-to-Consumer Advertising of Prescription-Only Drugs: Prescribed to Improve Consumer Welfare? Morgan SG, Mintzes B, Barer ML. Journal of Health Services Research and Policy. 2003 October;8(4):237-244.
Strangulation or Rationalization? Costs and Access in Canadian Hospitals. Barer ML, Morgan SG, Evans RG. Longwoods Review. 2003;1(4):10-19.
Whither Seniors' Pharmacare: Lessons From (and For) Canada. Morgan SG, Barer ML, Agnew JD. Health Affairs. 2003 May/June;22(3):49-59.
Predictive Genetic Tests and Health System Costs. Morgan S, Hurley J, Miller F, Giacomini M. Canadian Medical Association Journal [Commentary]. 2003 April 15;168(8):989-991.
Peeling the Onion: What Drives Pharmaceutical Expenditures in Canada. Morgan SG. Paper prepared for the Institute for Research on Public Policy (IRPP) conference Toward a National Strategy on Drug Insurance: Challenges and Priorities; 2002 September 23; Toronto, ON. Vancouver (BC): Centre for Health Services and Policy Research; December 2002. (22 pages)
Quantifying Components of Drug Expenditure Inflation: The British Columbia Seniors' Drug Benefit Plan. Morgan SG. Health Services Research. 2002 October;37(5):1243-66.
An Assessment of the Health System Impacts of Direct-To-Consumer Advertising of Prescription Medicines. Vol. V Morgan S. Predicting the Welfare and Cost Consequences of Direct-to-Consumer Prescription Drug Advertising. Vancouver (BC): Centre for Health Services and Policy Research; August 2001. (52 pages)
Influences on the Health Care Technology Cost-Driver. Morgan S, Hurley J. Paper prepared for the Commission on the Future of Health Care in Canada Discussion Paper Series, paper no. 14. Saskatoon (SK): Commission on the Future of Health Care in Canada; August 2002. (28 pages)
[An edited version of this paper appears in The Fiscal Sustainability of Health Care in Canada: The Romanow Papers, Volume 1, GP Marchildon, T McIntosh, and P-G Forest (eds.), Toronto (ON): University of Toronto Press, 2004, pp.27-50.]
Pressions sur la hausse des coûts induites par les technologies des soins de santé. Les études de la Commission sur l'avenir des soins de santé au Canada, étude No. 14. août 2002 (32 pages).
An Assessment of the Health System Impacts of Direct-To-Consumer Advertising of Prescription Medicines. Vol. I Mintzes B, Barer ML, Kazanjian A, Bassett K, Evans RG, Morgan S. Executive Summary.
Vancouver (BC): Centre for Health Services and Policy Research; February 2002. (11 pages)
Évaluation des effets, sur le système de santé, de la publicité des médicaments de prescription orientée directement vers le consommateur (PODC): Tome I: Résumé. février 2002. (13 pages)
Statistics and Drug Utilization: Are Prescribing Rates Really that High? Morgan S. Canadian Medical Association Journal. 2001 November 27;165(11):1507.
Download Supplementary Figures.
Price and Productivity Measurement in a Pharmaceutical Sector Sub-Market: The Real Cost of Treating Hypertension. Morgan S. Vancouver (BC): Centre for Health Services and Policy Research; November 2001. [Working Paper] (49 pages)
Apocalypse No: Population Aging and the Future of Health Care Systems. Evans RG, McGrail KM, Morgan SG, Barer ML, Hertzman C. Canadian Journal on Aging. 2001;20(suppl. 1):160-191.
Buying Science, Selling Drugs. Morgan SG, Barer ML, Evans RG. Health Matters. Winter 2000/01;43:12-13.
Health Economists Meet the Fourth Tempter: Drug Dependency and Scientific Discourse. Morgan S, Barer ML, Evans RG. Health Economics. 2000;9(8):659-667.
Quebec's Drug Insurance Plan: A Prescription For Canada? Morgan S. Vancouver (BC): Centre for Health Services and Policy Research; February 1998.
Issues for Canadian Pharmaceutical Policy. Morgan SG. In: Canada Health Action: Building on the Legacy. Papers Commissioned by the National Forum on Health. Volume 4: Health Care Systems in Canada and Elsewhere. Sainte-Foy (QC): Editions MultiMondes; 1998.
Evaluating Amendments to the Canadian Patent Act. Morgan S, Barer ML. Vancouver (BC): Centre for Health Services and Policy Research; January 1997.
